3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 4
1
Phase 3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
32
Colonic Neoplasms
20
Rectal Neoplasms
11
Carcinoma, Hepatocellular
7
Neoplasm Metastasis
5
Stomach Neoplasms
2
Neoplastic Cells, Circulating
2
Neoplasms
2
Liver Neoplasms
2
Recurrence
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Oligometastatic Gastric Adenocarcinoma
1
Neuroendocrine Tumors
1
Neoplasms, Second Primary
1
Neoplasm, Residual
1
Neoplasm Recurrence, Local
1
Margins of Excision
1
Locally Advanced Rectal Cancer
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
18
Cisplatin
13
Oxaliplatin
8
Capecitabine
7
Leucovorin
6
Fluorouracil
5
pembrolizumab
4
Photochemotherapy
3
Irinotecan
3
ivosidenib
2
Cholangiopancreatography, Endoscopic Retrograde
2
zanidatamab
1
toripalimab
1
pemigatinib
1
lenvatinib
1
infigratinib
1
durvalumab
1
cemiplimab
1
becatecarin
1
atezolizumab
1
Tissue Adhesives
1
Tegafur
1
Taxes
1
S 1 (combination)
1
Radiotherapy, Image-Guided
1
Radiation
1
Platinum
1
Pancreaticojejunostomy
1
Nivolumab
1
Neoadjuvant Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Cholangiocarcinoma
×
Folfox protocol
×
Clear all
NCT07265674
2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3
Recruiting
480 enrolled